ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Roche is licensing technology from the start-up Dyno Therapeutics for making the adeno-associated virus (AAV) vectors needed to deliver gene therapies to cells. Under the deal, Dyno will get an undisclosed up-front payment and up to $1.8 billion in milestones. In exchange, Dyno will use its CapsidMap technology to design AAV capsids for gene therapies from Roche and Roche’s Spark Therapeutics subsidiary. Target applications are diseases of the central nervous system and liver-directed therapies.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X